✦ LIBER ✦

Abatacept, a Novel CD80/86–CD28 T Cell Co-stimulation Modulator, in the Treatment of Rheumatoid Arthritis

✍ Scribed by Riku Korhonen; Eeva Moilanen

Book ID: 111316628
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 162 KB
Volume: 104
Category: Article
ISSN: 1742-7835
DOI: 10.1111/j.1742-7843.2009.00375.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Abatacept: a T-cell co-stimulation modul

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis

✍ Andrew J K Östör 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 487 KB

Abatacept: a T-cell co-stimulation modul

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis

✍ Andrew J. K. Östör 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 35 KB

CD28 co-stimulation is intact and contri

CD28 co-stimulation is intact and contributes to prolonged ex vivo survival of hyporesponsive synovial fluid T cells in rheumatoid arthritis

✍ Madelon M. Maurice; Ellen A. M. Van der Voort; Angela Leow; Nivine Levarht; Ferd 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 2 views

Interleukin-15 stimulates macrophages to

Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis?

✍ René Rückert; Katja Brandt; Martin Ernst; Kathleen Marienfeld; Elena Csernok; Cl 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB

Tumor-growth inhibition with bispecific

Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T-cell co-stimulation via CD28

✍ Ludger Grosse-Hovest; Martina Brandl; Mikael Dohlsten; Terje Kalland; Wolfgang W 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 144 KB 👁 2 views

T-cell co-stimulation by the CD28 ligand

T-cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor

✍ Pascal Chaux; Monique S. Martin; François Martin 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 732 KB

Cell variants from experimental tumors may lose their tumorigenicity or give rise to tumors that regress after a short period of progression in immunocompetent syngeneic animals. Rejection of these tumor cells is often 1-cell-dependent. It has recently been reported that, besides the specific signal